英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

07630 英派药业-B

休市中 08-14 16:08:34

12.840

+0.730

+6.03%

最高12.900	最低11.820	成交量50.87万
今开12.120	昨收12.110	日振幅8.92%
总市值36.27亿	流通市值36.27亿	总股本2.82亿
成交额634.84万	换手率0.18%	流通股本2.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派药业-B","latestPrice":12.84,"timestamp":1786694914842,"preClose":12.11,"halted":0,"volume":508679,"delay":0,"changeRate":0.06028075970272506,"floatShares":282461530,"shares":282461530,"eps":-1.5063640985992863,"marketStatus":"休市中","change":0.73,"latestTime":"08-14 16:08:34","open":12.12,"high":12.9,"low":11.82,"amount":6348436,"amplitude":0.089182,"askPrice":12.84,"askSize":400,"bidPrice":12.75,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-1.3496270255424336,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":7,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":12.11,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.6018398342394969,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630","defaultTab":"news","newsList":[{"id":"2659118951","title":"港股异动 | 英派药业-B(07630)涨超3% 预期中期取得亏损同比减少约22%至37% 已将IMP2794提名为PPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2659118951","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659118951?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:48","pubTimestamp":1786686502,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B涨超3%，截至发稿，涨2.64%，报12.43港元，成交额306.36万港元。此外，英派药业-B公告称，公司已将IMP2794提名为临床前候选化合物，为一款 KAT6A特异性降解PROTAC。IMP2794是英派药业依托其自有的靶向蛋白降解平台发现的首个PCC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4212","BK4585","PPC","BK4588","07630","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111945504","title":"英派药业-B（07630）首款自研KAT6A高特异性PROTAC IMP2794获选为临床前候选化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=1111945504","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111945504?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:20","pubTimestamp":1786526458,"startTime":"0","endTime":"0","summary":"2026年8月12日，英派药业-B公布，其已正式将IMP2794提名为临床前候选化合物。IMP2794为一款针对KAT6A的高特异性蛋白降解靶向嵌合体，系公司依托自有靶向蛋白降解平台发现的首个PCC。公告披露，IMP2794可高效、选择性地降解KAT6A，对同源蛋白KAT6B的选择性超过1,000倍。英派药业-B提醒，根据香港联合交易所有限公司证券上市规则第18A.05条，公司无法保证最终能够成功开发、制造及／或商业化IMP2794。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658780479","title":"英派药业-B(07630)提名IMP2794为临床前候选化合物(PCC) 一款源自公司自有靶向蛋白降解平台的KAT6A高特异性PROTAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658780479","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658780479?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:17","pubTimestamp":1786526237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，英派药业已将IMP2794提名为临床前候选化合物，为一款 KAT6A特异性降解PROTAC。IMP2794是英派药业依托其自有的靶向蛋白降解平台发现的首个PCC。IMP2794是一种高效且选择性作用于KAT6A的降解剂，对KAT6B的选择性超过1000倍。IMP2794在敏感、非敏感乳腺癌CDX模型中均展现出优异的体内抗肿瘤效果。同时，对KAT6B的抑制与潜在的血液毒性相关。公司已建立依托E3配体库与连接子库的降解平台，可快速组装口服生物利用度优异的PROTAC分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B(07630)提名IMP2794为临床前候选化合物(PCC) 一款源自公司自有靶向蛋白降解平台的KAT6A高特异性PROTAC","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2658911994","title":"营收暴增无阻英派药业继续亏损：预计上半年减亏三成左右！股价早已破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911994","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658911994?lang=zh_cn&edition=full","pubTime":"2026-08-11 23:03","pubTimestamp":1786460583,"startTime":"0","endTime":"0","summary":"8月11日，英派药业(07630.HK)发布盈利预告，公司预计2026年上半年收入约9470万元至1.16亿元，较去年同期约2520万元增长约276%至359%；预计期内亏损约8170万元至9990万元，较去年同期约1.29亿元减少约22%至37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838249182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838249182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","07630","EIKN","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170386983","title":"英派药业-B预计中期营收最高增逾三倍 亏损显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1170386983","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170386983?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:47","pubTimestamp":1786438063,"startTime":"0","endTime":"0","summary":"英派药业-B8月11日发布盈利预告称，预计截至2026年6月30日止六个月的收入约94.7百万元至约1.16亿元，较2025年同期的25.2百万元增长约276%至359%。同期公司预计录得期内亏损约81.7百万元至99.9百万元，较上一年度同期的128.7百万元减少约37%至22%。\\n\\n英派药业-B预计将在2026年8月公布中期业绩。公司提醒投资者在买卖公司证券时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899307","title":"英派药业-B(07630.HK)预期中期取得亏损约8170万元至9990万元 同比减少约22%至37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658899307?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:47","pubTimestamp":1786438054,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120585564","title":"英派药业-B7月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120585564","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120585564?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:25","pubTimestamp":1785921932,"startTime":"0","endTime":"0","summary":"英派药业-B（股票代码：07630）于2026年8月5日发布了截至2026年7月31日的证券变动月报表。报告显示，公司上月底已发行普通股（H股）总数为282,461,530股，本月无增加或减少，月末结存仍为282,461,530股。注册股本保持人民币282,461,530元，且未有任何库存股份变动。公司指出，目前已满足香港联交所对于公众持股量的相关要求。\n报告并未披露任何股份期权或股权激励计划的授出、行使或失效事件，亦无新增发行、购回或注销股份记录。公司股本结构在本月维持不变。公告由执行董事兼首席执行官蔡遂雄签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656323387","title":"港股异动 | 英派药业-B(07630)午后跌超13% 7月初至今累跌近七成 总市值已不足35亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656323387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656323387?lang=zh_cn&edition=full","pubTime":"2026-08-03 14:09","pubTimestamp":1785737359,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，英派药业-B午后跌超13%，截至发稿，跌12.47%，报11.58港元，成交额527.74万港元。英派药业最高可收获总计4.235亿欧元款项。值得注意的是，市场此前普遍预测，因为英派药业满足港股通市值要求，将于2026年9月顺利纳入港股通。据悉，本次9月港股通调整，6月30日收盘市值是考核基准。然而考核落地后该股快速杀跌，7月2日暴跌45%，此后股价继续阴跌。截至8月3日，市值已不足35亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","BK4585","07630","KCAI","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122801606","title":"英派药业-B(07630)发布《董事会审计委员会工作规程》 明确审计委员会权限与运作","url":"https://stock-news.laohu8.com/highlight/detail?id=1122801606","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122801606?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:00","pubTimestamp":1785499247,"startTime":"0","endTime":"0","summary":"2024年X月XX日，英派药业-B公告披露《南京英派药业股份有限公司董事会审计委员会工作规程》，以强化董事会决策功能、完善内部控制并确保有效监督。委员会主席由独立非执行董事担任。公司承诺向审计委员会提供履职所需资源。英派药业-B表示，《工作规程》的实施将进一步规范审计委员会运作，强化公司治理结构，并确保持续满足《公司法》及《上市规则》要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655330921","title":"英派药业与法玛诺唯亚签署独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2655330921","media":"中国财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655330921?lang=zh_cn&edition=full","pubTime":"2026-07-31 14:28","pubTimestamp":1785479299,"startTime":"0","endTime":"0","summary":"7月30日，英派药业（07630.HK）宣布与法玛诺唯亚Pharmanovia签订独家许可合作协议，授予其在欧洲、中东、北非、澳大利亚及新西兰地区对塞纳帕利（senaparib）用于晚期上皮性高级别卵巢癌、输卵管癌及原发性腹膜癌维持单药治疗的独家生产、研发及商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828228360.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828228360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655233805","title":"英派药业-B早盘涨超11% 授治疗癌症产品塞纳帕利独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2655233805","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655233805?lang=zh_cn&edition=full","pubTime":"2026-07-31 09:45","pubTimestamp":1785462300,"startTime":"0","endTime":"0","summary":"模拟交易客户端英派药业-B早盘涨超11%，截至发稿，股价上涨11.02%，报12.79港元，成交额99.69万港元。7月30日，英派药业宣布与全球专业制药公司Pharmanovia达成独家合作，授予Pharmanovia在欧洲、中东、北非、澳大利亚及新西兰地区对塞纳帕利用于晚期上皮性高级别卵巢癌、输卵管癌及原发性腹膜癌维持单药治疗的独家生产、研发及商业化权利。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-31/doc-iniksaik9401431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655384803","title":"港股异动 | 英派药业-B(07630.HK)涨近10% 授治疗癌症产品塞纳帕利独家权利 或获最多逾4亿欧元及特许权费","url":"https://stock-news.laohu8.com/highlight/detail?id=2655384803","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655384803?lang=zh_cn&edition=full","pubTime":"2026-07-31 09:34","pubTimestamp":1785461681,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655873808","title":"英派药业-B(07630.HK)与PHARMANOVIA就塞纳帕利于欧洲、中东及北非、澳洲及新西兰签订独家授权协议 有望获得总计最高达4.235亿欧元的交易对价","url":"https://stock-news.laohu8.com/highlight/detail?id=2655873808","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655873808?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:20","pubTimestamp":1785406817,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164331807","title":"英派药业-B与Pharmanovia达成Senaparib在欧洲、中东、北非、澳大利亚及新西兰的独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1164331807","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164331807?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:19","pubTimestamp":1785406779,"startTime":"0","endTime":"0","summary":"英派药业-B（IMPACT THERAP-B，股票代码：07630）近日宣布，已与Pharmanovia公司签署了一项独家许可协议。根据该协议，英派药业将其在研药物Senaparib的权益授予Pharmanovia，覆盖范围广泛，包括欧洲、中东、北非、澳大利亚以及新西兰等地区。这一战略合作不仅弥补了英派药业在相关区域的布局空白，也为其全球扩张注入了新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145155539","title":"英派药业-B 2026年首场临时股东会通过股份奖励计划及章程修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1145155539","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145155539?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:56","pubTimestamp":1785149762,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司7月27日公告，其2026年第一次临时股东会已于2026年7月27日召开，并就两项特别决议进行投票表决。上述两项议案均获得三分之二以上赞成票，按特别决议正式通过。截至股东会召开日，公司已发行H股总数为282,461,530股。经股东批准的组织章程细则修订自2026年7月27日起生效。修订后的章程将刊载于香港联交所网站及公司官网。全部执行董事、非执行董事及独立非执行董事均以现场或电子方式参加会议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654060630","title":"英派药业-B(07630.HK)：将IMP3201提名为临床前候选化合物(PCC)，为一款全新、同类首创(FIC)、靶向CEACAM5的双载荷ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654060630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654060630?lang=zh_cn&edition=full","pubTime":"2026-07-27 07:41","pubTimestamp":1785109287,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148850396","title":"英派药业-B（07630）宣布首款靶向CEACAM5双载荷ADC IMP3201获选临床前候选化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=1148850396","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148850396?lang=zh_cn&edition=full","pubTime":"2026-07-27 07:35","pubTimestamp":1785108932,"startTime":"0","endTime":"0","summary":"2026年7月27日，英派药业-B发布自愿公告称，公司已正式将IMP3201提名为临床前候选化合物。IMP3201是一款同类首创、靶向CEACAM5的双载荷抗体-药物偶联物，基于公司自主研发的支链连接子双载荷ADC技术平台开发，是该平台产出的首个PCC。根据香港联合交易所有限公司证券上市规则第18A.05条，英派药业-B提醒股东及潜在投资者：公司无法保证最终能够成功开发、制造及/或商业化IMP3201，投资者在买卖公司股份时应保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652684382","title":"英派药业-B(07630)：多项研究结果摘要获接受于2026年欧洲肿瘤内科学会大会作壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2652684382","media":"智通财经网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652684382?lang=zh_cn&edition=full","pubTime":"2026-07-20 07:38","pubTimestamp":1784504331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，三个主要管线项目的最新临床数据已获接受于2026年欧洲肿瘤内科学会大会作壁报展示。欧洲肿瘤内科学会大会是全球肿瘤学领域最具影响力的学术会议之一，本年度的大会将于2026年10月23日至27日在西班牙马德里举行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B(07630)：多项研究结果摘要获接受于2026年欧洲肿瘤内科学会大会作壁报展示","news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176490454","title":"英派药业-B（07630）三项管线最新数据获2026年ESMO大会壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1176490454","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176490454?lang=zh_cn&edition=full","pubTime":"2026-07-20 07:35","pubTimestamp":1784504139,"startTime":"0","endTime":"0","summary":"2026年7月20日，英派药业-B发布自愿公告称，公司三项核心管线项目的最新临床研究数据获欧洲肿瘤内科学会2026年大会接纳，并将在10月23日至27日于西班牙马德里举行的会议上以壁报形式展示。其欧洲上市许可申请已于2025年8月获欧洲药品管理局受理，预计2026年下半年可获批。英派药业-B提示，根据香港联交所《上市规则》第18A.05条，公司无法保证塞纳帕利在新增适应症的开发一定成功，也无法保证IMP1734及IMP1707最终获批上市。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193557412","title":"英派药业-B（07630）拟设立股份奖励计划 并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1193557412","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193557412?lang=zh_cn&edition=full","pubTime":"2026-07-10 21:30","pubTimestamp":1783690255,"startTime":"0","endTime":"0","summary":"2026年7月10日，英派药业-B公告称，董事会已决议向股东大会提呈两项议案：一是建议采纳《2026年股份奖励计划》，二是建议修订公司组织章程细则。上述两项议案均须经公司股东在临时股东大会上审议并获通过后方可生效。截至公告披露日，英派药业-B董事会成员包括：执行董事蔡遂雄博士、田野博士、马宁女士；非执行董事徐聪博士、Qiang Xu博士、刘涛先生；独立非执行董事郭明博士、萧志雄先生、邵黎明博士。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0264},{"period":"1month","weight":-0.2316},{"period":"3month","weight":-0.6793},{"period":"6month","weight":-0.3612},{"period":"ytd","weight":-0.3612}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京英派药业股份有限公司是一家主要从事生物技术研发和商业化的中国公司。该公司处于商业化阶段。该公司致力于在全球范围内推进基于合成致死（SL）机制的精准抗癌疗法。该公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌（OC）一线维持疗法。该公司正在研发的产品管线包PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等。","exchange":"SEHK","name":"英派药业-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英派药业-B,07630,英派药业-B股票,英派药业-B股票老虎,英派药业-B股票老虎国际,英派药业-B行情,英派药业-B股票行情,英派药业-B股价,英派药业-B股市,英派药业-B股票价格,英派药业-B股票交易,英派药业-B股票购买,英派药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}